News & Updates
Showing Oncology articles
Showing
GLP-1 RAs may improve survival in cancer patients
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes and cancer results in significantly reduced mortality and hospitalizations relative to treatment with metformin, a study has shown.
GLP-1 RAs may improve survival in cancer patients
27 May 2026
When is better to administer ICIs to NSCLC patients: AM or PM?
A study from the US finds that compared with afternoon infusions, morning infusions of immune checkpoint inhibitors (ICI) confer a modest but clinically meaningful overall survival (OS) benefit to patients with non-small-cell lung cancer (NSCLC).
When is better to administer ICIs to NSCLC patients: AM or PM?
27 May 2026
Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.
Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
21 May 2026
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
The addition of capivasertib to fulvestrant improves time to second progression (PFS2) and time to first subsequent chemotherapy or death (TTFSC) in PIK3CA/AKT1/PTEN-altered patients with HR+/HER2- advanced breast cancer and the overall population, suggesting a clinically meaningful benefit when compared with placebo plus fulvestrant, as shown in the phase III CAPItello-291 trial.